Aim-The assessment of the value of the antibody QBEND10, which is directed against the haemopoietic stem cell related antigen CD34, in the immunohistochemical diagnosis of myelodysplastic syndrome in routinely processed bone marrow biopsy specimens. Methods-581 formalin fixed, paraffin embedded trephine biopsy specimens of the iliac crest were immunostained with QBEND1O (avidin-biotin complex/ABC method). The number of CD34 + haemopoietic stem cells/blast cells (referred to hereafter as CD34 + cells) was determined in each case. The Wilcoxon test was used for statistical analysis. Results-The following diagnostic categories were defined: (1) normal or reactive bone marrow (n = 356), (2) lymphoproliferative disorders, usually non-Hodgkin's lymphoma of low grade malignancy or multiple myeloma (n = 118), (3) myelodysplastic syndrome (n = 22), (4) acute leukaemia (n = 44), and (5) myeloproliferative diseases (n = 41). The average number of CD34 + cells was very low (0.2/HPF) in normal and reactive bone marrow, in lymphoproliferative disorders and in the myelodysplastic syndrome subtypes RA and RARS. Myeloproliferative diseases showed an average of three CD34 + cells/HPF. However, the average number of CD34 + cells was significantly higher (p<0.05) in the myelodysplastic syndrome subtypes RAEB and RAEB-T
low (0.2/HPF) in normal and reactive bone marrow, in lymphoproliferative disorders and in the myelodysplastic syndrome subtypes RA and RARS. Myeloproliferative diseases showed an average of three CD34 + cells/HPF. However, the average number of CD34 + cells was significantly higher (p<0.05) in the myelodysplastic syndrome subtypes RAEB and RAEB-T (8.7/HPF) and in acute leukaemia (in- cluding both myeloid and lymphoblastic leukaemia; 11I*7/HPF). Conclusions-QBEND1O is ofvalue for the identification of RAEB and RAEB-T in routinely processed bone marrow biopsy specimens because it enables the detection of even small increases in the number of CD34+ cells. The myelodysplastic syndromes have been classified by the French-American-British (FAB) cooperative group into five separate categories.' The number ofblast cells is an important factor here: it is usually low in refractory anaemia (RA), refractory anaemia with ringed sideroblasts (RARS), and chronic myelomonocytic leukaemia.' By definition, it is increased in the subtypes "refractory anaemia with excess of blast cells" (RAEB) and "refractory anaemia with excess of blast cells in transformation" (RAEB-T). It may be difficult to define the subtype using routinely processed (formalin fixed, paraffin embedded) bone marrow biopsy specimens, especially when blood and bone marrow smears are not available to the haematopathologist for comparison. The pathognomonic ringed sideroblasts cannot be identified in routinely processed bone marrow biopsy specimens because mitochondrial iron deposits remain unstained by the Prussian blue stain. Various histopathological findings have been found to be associated to varying extents with myelodysplastic syndromes, for example abnormally localised immature myeloid precursor cells (the so called ALIP phenomenon),3 megakaryocyte atypia, especially an increase in micromegakaryocytes,4 and fibrosis5 and oedema6 of the marrow stroma. These findings are all either non-specific (fibrosis, oedema) or The myeloproliferative disorders, taken together, showed a considerably larger average number of CD34 + cells (3/HPF), but the difference was not statistically significant. Although the average in all the cases of agnogenic myeloid metaplasia and polycythaemia rubra vera was comparable to that in normal/reactive marrow, it was moderately increased in five of the 25 cases of chronic myeloid leukaemia. All these five patients were clinically in the accelerated phase of the disease but not in an overt blast crisis.
The number of CD34 + cells was significantly higher (p<0 05) in the myelodysplastic syndrome subtypes RAEB and RAEB-T, amounting to 8 7/HPF. It was highest in acute leukaemia (both myeloid and lymphoid), in which it reached an average of nearly 112/HPF, although about 50% of the specimens did not show any increase in CD34 expression. The results of the semiquantitative analysis are summarised in table 3. Moderate and large numbers of CD34 + blast cells were confined almost exclusively to the myelodysplastic subtypes RAEB and RAEB-T, acute leukaemia, and a small proportion of the cases of myeloproliferative disorder. Most of the specimens of normal or reactive marrow and marrow infiltrated by lymphoproliferative disorders or myelodysplastic syndrome subtypes RA and RARS contained only small numbers of CD34+ cells or none at all. However, four specimens of normal or reactive marrow (two derived from children with slight hypocellularity of the bone marrow but intact haemopoiesis) and one specimen with infiltration by non-Hodgkin's lymphoma of low grade malignancy showed a moderate increase in CD34 + haemopoietic progenitor cells.
Discussion
The expression of the glycoprotein CD34 is highly restricted to a crucial subset of haemopoietic progenitor cells and is found on 1-4% of human bone marrow cells.'" Little is known about its functional properties, but it was shown recently that monoclonal antibodies against 0-sialoglycoprotease sensitive epitopes of CD34, (including QBEND 10, which was also used in this study) induce actin polymerisation in CD34 + haemopoietic cells, with subsequent strongly enhanced cytoadhesiveness."1 CD34 expression declines progressively as the progenitor cells differentiate and become committed to particular lineages. '2 The findings of this immunohistochemical study are well in accord with those of FACS analysis, which has shown a very low incidence of CD34+ haemopoietic cells in normal and reactive bone marrow. It is difficult to explain why CD34 + haemopoietic cells could not be detected immunohistochemically in a considerable proportion of our cases. It is possible that in routinely processed trephine specimens only the very immature (totipotent) haemopoietic stem cells with relatively strong expression of CD34 are immunostained, and the committed progenitor cells with reduced expression of CD34 remain unstained. This hypothesis is supported by the fact that the number of CD34-immunoreactive haemopoietic cells increases slightly in some cases after microwave treatment (our unpublished observations). The most important result of our study is probably thie finding that the application of QBEND10 on routinely processed bone marrow biopsy specimens enables identification of the myelodysplastic syndrome subtypes RAEB and RAEB-T, because the numbers of CD34 + blast cells here were significantly greater than in normal of reactive marrow. It must be emphasised that only these two subtypes showed a significant increase in CD34 + cells. The RA and RARS subtypes showed no such increase, as might be expected from the low blast cell count found in bone marrow smears in these subtypes. 2 13 14 One further conclusion concerning the myeloproliferative syndromes can be drawn from our immunohistological findings. Because an increase in CD34+ cells was noted in the accelerated phase ofchronic myeloid leukaemia but not in chronic phase disease, immunostaining of trephine biopsy specimens with an appropriate antibody could be useful for identifying patients in the accelerated phase.
About a third ofthe cases ofacute leukaemia, including leukaemias both of myeloid and of lymphoid origin, showed expression of CD34 by the majority of the blast cells. A similar frequency of CD34 expression in acute leukaemia was reported in a study in which a clear correlation between flow cytometric and immunohistological findings was also found in such cases. '5 The expression of CD34 by the blast cells therefore does not allow identification of the cell lineage involved. 
